Rather than riding off into the sunset after successfully developing a biotech company and getting it sold to a big pharma, many CEOs start anew, trying to show that lightning can strike twice (or more).
Biomedical Advanced Research and Development Authority (BARDA), which evolved out of the biodefense-focused Project BioShield, has moved beyond simply funding drugs and devices that might be used in the event of terrorism.
Biomedical Advanced Research and Development Authority (BARDA), which evolved out of the biodefense-focused Project BioShield, has moved beyond simply funding drugs and devices that might be used in the event of terrorism. The division of the U.S. Department of Health and Human Services now prefers to help develop dual-use products that can have an immediate benefit to public health as well as a guarding against potential terrorism.
Nearly 60 years after tardive dyskinesia (TD) was recognized as a disease, patients may soon have a drug approved to treat their involuntary movements.
More than two years after the Jumpstart Our Business Startups (JOBS) Act was signed into law, Title III of the act, which allows for equity-based crowdfunding from non-accredited investors, still hasn't been implemented by the SEC.
Claravant Analytics LLC is looking to become the drug industry's version of a credit rating agency, doing independent reviews of a drug's likelihood of gaining regulatory approval.
The attention deficit hyperactivity disorder (ADHD) market is $10 billion strong, but grabbing a piece of the pie with so many drugs already on the market, including some generics, requires differentiation.
